Supercharged immune cells take on Virus-Linked cancers

NCT ID NCT01555892

First seen Nov 16, 2025 · Last updated May 16, 2026 · Updated 18 times

Summary

This study tests a new way to make special immune cells (T cells) that can attack cancer cells infected with the Epstein-Barr virus (EBV). The cells are grown faster in the lab and given to patients with Hodgkin or non-Hodgkin lymphoma, or related diseases that have come back or not gone away. The main goal is to find the safest dose and see what side effects occur. Up to 136 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harris Health System (includes ben Taub General Hospital and Smith)

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.